
Key Points
- 01FDA clears Klygefa for adults with AChR antibody–positive gMG
- 02European Commission approves Klygefa as add-on therapy in AChR-positive gMG
- 03Phase 3 PREVAIL trial in 260 patients met its primary MG-ADL endpoint
- 04Klygefa is a once-weekly, self-administered dual-binding C5 inhibitor
US and EU approvals for AstraZeneca’s Klygefa
AstraZeneca’s rare disease business Alexion has secured major regulatory milestones with the approval of gefurulimab (Klygefa) for anti-acetylcholine receptor (AChR) antibody–positive generalized myasthenia gravis (gMG) in both the United States and the European Union. On November 16, 2026, the FDA approved once-weekly, subcutaneous, self-administered Klygefa for adults with AChR antibody–positive gMG, while the European Commission authorized it as an add-on to standard therapy for adults with the same condition.
These decisions position Klygefa as a new treatment option across two of the largest pharmaceutical markets, targeting a rare autoimmune disease characterized by reduced muscle function and severe muscle weakness. The EU authorization makes Klygefa the first and only approved dual-binding nanobody C5 inhibitor in that region, offering once-weekly subcutaneous self-administration via autoinjector.
Clinical evidence from the PREVAIL phase 3 trial
Both the US and EU approvals are underpinned by the global phase 3 PREVAIL study (ALXN1720-MG-301; NCT05556096), a randomized, double-blind, placebo-controlled trial in adults with AChR antibody–positive gMG. PREVAIL enrolled 260 patients from 20 countries, who were randomized 1:1 to Klygefa or placebo for 26 weeks, following a single weight-based loading dose on day 1 and weekly maintenance dosing beginning on day 8.
The trial met its primary endpoint, showing a statistically significant improvement from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 versus placebo, with a treatment difference of -1.6 points and a reported p value of less than 0.0001. Clinically meaningful improvement in MG-ADL was observed as early as week one and was sustained through week 26, with additional data indicating improvements in Quantitative Myasthenia Gravis scores and reduced need for rescue therapy favoring active treatment.
Investigators describe the PREVAIL results as demonstrating rapid and durable disease control with Klygefa, and an open-label extension is ongoing to further evaluate long-term safety and efficacy. PREVAIL findings have been presented at neuromuscular scientific meetings and published in JAMA Neurology, supporting the robustness of the data package submitted to regulators.
Mechanism of action and dosing convenience
Klygefa (gefurulimab) is a complement C5 inhibitor described as a novel dual-binding nanobody optimized for subcutaneous self-administration in adults with AChR antibody–positive gMG. The molecule binds the C5 protein in the terminal complement cascade, a part of the immune system that, when activated in an uncontrolled manner, can cause the body to attack healthy cells at the neuromuscular junction.
Gefurulimab also binds serum albumin, extending its half-life and enabling once-weekly dosing. The drug is administered via a subcutaneous autoinjector, allowing patients to self-administer treatment and offering a convenience advantage compared with intravenous C5 inhibitors that require infusions at multi-week intervals.
Safety profile and global footprint
Across clinical development, Klygefa was generally well tolerated, with a safety profile described as consistent with earlier gMG experience for C5 inhibitors eculizumab and ravulizumab. Treatment-emergent adverse event rates were similar between gefurulimab and placebo in PREVAIL, and most events were grade 1 or 2 in severity. The most common adverse events reported with Klygefa included injection-site reactions, back pain and vomiting.
Beyond the new US and EU decisions, Klygefa is already approved in Japan and other countries for certain adults with gMG, and regulatory submissions supported by PREVAIL are under review in China and additional markets. In Europe, an estimated 82,500 people have been diagnosed with gMG across Germany, France, the UK, Italy and Spain, of whom about 66,000 are AChR antibody–positive, underscoring the potential reach of the newly approved therapy.
Key Takeaways
- 01Klygefa’s coordinated approvals in the US and EU create a broad new option for adults with AChR antibody–positive generalized myasthenia gravis.
- 02The PREVAIL phase 3 trial provides consistent, statistically significant evidence of early and sustained functional benefit over 26 weeks.
- 03Once-weekly, self-administered subcutaneous dosing and dual-binding nanobody design distinguish Klygefa within the complement C5 inhibitor class.
References
- https://finance.yahoo.com/healthcare/articles/astrazeneca-secures-us-eu-nod-160200451.html?.tsrc=rss
- https://www.biopharminternational.com/view/fda-approves-astrazeneca-gefurulimab-klygefa-generalized-myasthenia-gravis
- https://allsci.com/news/approvals/klygefa-gefurulimab-eu-approves-alexions-billed/
- https://news.europawire.eu/european-commission-clears-astrazenecas-once-weekly-klygefa-for-adults-with-generalised-myasthenia-gravis/eu-press-release/2026/11/16/14/06/06/188052/